323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III

Prothrombin complex concentrate in managing direct oral anticoagulant DOAC associated bleeding and real world use in vitamin k antagonist VKA associated bleeding The ongoing lex 210 and lex 212 studies

Susoctocog alfa for major surgery in acquired Hemophilia A

Burden of vitamin d deficiency and bone health risk factors in persons with von Willebrand disease in Arkansas

National trends and demographic disparities in mortality due to bleeding disorders in the u S 1999–2020

The Mayo Clinic enterprise experience and outcomes of perioperative utilization of recombinant factor VIIa rFVIIa NovoSeven®

A novel VWF mutation associated with macrothrombocytopenia cytoskeletal defects and distinct functional abnormalities A case report

Fibrinogen concentrate versus cryoprecipitate for bleeding in cardiac surgery patients stratified by surgery risk in the phase 3 fibres Study

Response to TFPI inhibition in severe factor v deficiency with a novel compound heterozygous mutation

Systematic literature review and meta analysis on the safety of fibrinogen concentrate versus cryoprecipitate in bleeding surgical patients

Comparative analysis of prophylaxis with 1 1 ratio pdVWF FVIII concentrate vs recombinant VWF in type 3 von willebrand disease adults in the United States Clinical and economic perspective

Real world study of population pharmacokinetic guided pdVWF FVIII 1 1 prophylaxis in people with severe von Willebrand disease The PopPK WILPROPHY study

Plasma derived VWF FVIII prophylaxis in children under 6 with VWD First results from wil 33

Use of emicizumab in patients with acquired hemophilia A An interim safety analysis of a large scale post‑marketing surveillance study